Logo image of TLSA

TIZIANA LIFE SCIENCES LTD (TLSA) Stock Fundamental Analysis

NASDAQ:TLSA - Nasdaq - BMG889121031 - Common Stock - Currency: USD

0.9  -0.02 (-2.45%)

Premarket: 0.9 0 (0%)

Fundamental Rating

1

Taking everything into account, TLSA scores 1 out of 10 in our fundamental rating. TLSA was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of TLSA have multiple concerns. TLSA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TLSA had negative earnings in the past year.
In the past year TLSA has reported a negative cash flow from operations.
TLSA had negative earnings in each of the past 5 years.
TLSA had a negative operating cash flow in each of the past 5 years.
TLSA Yearly Net Income VS EBIT VS OCF VS FCFTLSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

TLSA has a worse Return On Assets (-125.21%) than 80.99% of its industry peers.
TLSA's Return On Equity of -740.05% is on the low side compared to the rest of the industry. TLSA is outperformed by 82.42% of its industry peers.
Industry RankSector Rank
ROA -125.21%
ROE -740.05%
ROIC N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSA Yearly ROA, ROE, ROICTLSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K -1.5K

1.3 Margins

TLSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSA Yearly Profit, Operating, Gross MarginsTLSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

TLSA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TLSA has more shares outstanding
The debt/assets ratio for TLSA is higher compared to a year ago.
TLSA Yearly Shares OutstandingTLSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
TLSA Yearly Total Debt VS Total AssetsTLSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

TLSA has an Altman-Z score of 0.14. This is a bad value and indicates that TLSA is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.14, TLSA is doing good in the industry, outperforming 63.77% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that TLSA is not too dependend on debt financing.
TLSA has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 0.14
ROIC/WACCN/A
WACCN/A
TLSA Yearly LT Debt VS Equity VS FCFTLSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

TLSA has a Current Ratio of 0.85. This is a bad value and indicates that TLSA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.85, TLSA is doing worse than 90.41% of the companies in the same industry.
TLSA has a Quick Ratio of 0.85. This is a bad value and indicates that TLSA is not financially healthy enough and could expect problems in meeting its short term obligations.
TLSA has a Quick ratio of 0.85. This is amonst the worse of the industry: TLSA underperforms 89.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.85
TLSA Yearly Current Assets VS Current LiabilitesTLSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

TLSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.54%, which is quite impressive.
EPS 1Y (TTM)27.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TLSA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.33%
EPS Next 2Y3.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TLSA Yearly Revenue VS EstimatesTLSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
TLSA Yearly EPS VS EstimatesTLSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLSA. In the last year negative earnings were reported.
Also next year TLSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSA Price Earnings VS Forward Price EarningsTLSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSA Per share dataTLSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.28%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TIZIANA LIFE SCIENCES LTD

NASDAQ:TLSA (2/20/2025, 8:00:01 PM)

Premarket: 0.9 0 (0%)

0.9

-0.02 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-11 2024-06-11/amc
Earnings (Next)N/A N/A
Inst Owners0.9%
Inst Owner Change-48.49%
Ins Owners38.17%
Ins Owner ChangeN/A
Market Cap99.59M
Analysts82.86
Price Target3.06 (240%)
Short Float %1.71%
Short Ratio1.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 53.69
P/tB 53.69
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.21%
ROE -740.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.85
Altman-Z 0.14
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
EPS Next Y13.33%
EPS Next 2Y3.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.07%
OCF growth 3YN/A
OCF growth 5YN/A